论文部分内容阅读
目的：评价沙美特罗/丙酸氟替卡松（ SFP ）联合噻托溴铵（ TP ）治疗老年慢性阻塞性肺疾病（ COPD）的临床疗效及安全性。方法将2010-01-2011-12我科收治的老年COPD患者77例，随机分为试验组（ SFP联合TP ）36例，对照组（单纯SFP）41例。评价2组患者治疗2个月后客观评价指标（肺功能）及患者主观感受（呼吸困难评分，生活质量评分）改善情况。结果与治疗前相比，2组患者肺功能指标及主观感受均明显改善（ P＜0.05）。治疗2个月后，试验组呼吸困难评分[（1.6±0.3） vs （2.2±0.5）]，生活质量评分[（41.2±6.2） vs （48.4±8.9）]明显低于对照组；试验组1秒用力呼气容积（FEV1）[（1.54±0.22） vs （1.41±0.19）]， FEV1/用力肺活量（ FVC ）[（66.32±8.21） vs （59.66±7.87）]明显高于对照组，差别均有统计学意义（P＜0.05）。2组患者主要不良反应为口干和便秘，差别无统计学意义（ P＞0.05）。结论 SFP联合TP治疗老年COPD的主客观临床疗效均好于单用SFP组。“,”Objective To evaluate the clinical efficacy and safety of sal-meterol/fluticasone propionate(SFP) combined with tiotropium (TP) in eld-erly patients with chronic obstructive pulmonary disease (COPD).Methods Seventy-seven elderly patients with COPD were divided into the treat-ment group(SFP+TP)(n=36) and control group (n=41) treated with sal-meterol and fluticasone only.After two months treatment , the lung function indicator and subjective feelings(dyspnea score, quality of life) between the two groups were compared.Results The lung function and subjective feel-ings were improved in the both groups (P<0.05).After two months treat-ment, the dyspnea score (1.6 ±0.3) vs (2.2 ±0.5) and life quality scores (41.2 ±6.2) vs (48.4 ±8.9) in treatment group were much lower than those in control group (P<0.05).The forced expiratory volume in one sec-ond(FEV1) (1.54 ±0.22 vs 1.41 ±0.19) and FEV1/forced vital capacity (FVC) (66.32 ±8.21) vs (59.66 ±7.87) in the treatment group were much higher than those in control group ( P0.05).Conclusion The combined treatment regimen of SFP and TP was superior to the single regimen in the aspect of objective and sub-jective clinical efficacy .